Clinical Trials Directory

Trials / Conditions / Refractory Malignant Glioma

Refractory Malignant Glioma

12 registered clinical trials studyying Refractory Malignant Glioma — 1 currently recruiting.

StatusTrialSponsorPhase
RecruitingLutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
NCT05278208
Nationwide Children's HospitalPhase 1 / Phase 2
Active Not RecruitingSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating
NCT04320888
National Cancer Institute (NCI)Phase 2
Active Not RecruitingTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter
NCT04284774
National Cancer Institute (NCI)Phase 2
Active Not RecruitingIvosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat
NCT04195555
National Cancer Institute (NCI)Phase 2
Active Not RecruitingVolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
NCT03598244
National Cancer Institute (NCI)Phase 1
CompletedPalbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly
NCT03526250
National Cancer Institute (NCI)Phase 2
Active Not RecruitingErdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H
NCT03210714
National Cancer Institute (NCI)Phase 2
Active Not RecruitingEnsartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi
NCT03213652
National Cancer Institute (NCI)Phase 2
CompletedTazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or
NCT03213665
National Cancer Institute (NCI)Phase 2
CompletedOlaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist
NCT03233204
National Cancer Institute (NCI)Phase 2
Active Not RecruitingLarotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or
NCT03213704
National Cancer Institute (NCI)Phase 2
Active Not RecruitingGenetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
NCT02208362
City of Hope Medical CenterPhase 1